Morgan Stanley: The Biotech Stock With The Most Upside In 2015

In its recent annual Big Debates report, Morgan Stanley named Biogen Idec Inc. BIIB as its top large-cap biotech stock pick for 2015. Analysts are impressed with Biogen’s robust drug pipeline and feel that very little of the company’s potential is currently priced into the stock.
The pipeline
Anaysts see at least five drugs in Biogen’s pipeline that could contribute to the company’s future valuation. Morgan Stanley sees about $60 per share of value in BIIB037, an anti Aβ-human monoclonal antibody that Biogen is testing as a treatment for Alzheimer’s Disease and acute optic neuritis (AON).
Biogen is also expecting data in 2015 on its drug Tysabri, which is currently being tested for treatment of patients with secondary-progressive multiple sclerosis.
The projections
At around $343 per share, Biogen stock is already up more than 22 percent this year.